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CRITICAL ISSUES IN PREVENTING POST-
THROMBOTIC RE-ULCERATION
—Peter Pappas, MD, Newark, NJ
The lack of effective therapies and the recurrent nature
of chronic venous insufficiency (CVI) place a heavy burden
on the United States healthcare system. The population-
based costs in the United States for treatment of CVI and
venous ulcer care has been estimated at over one billion
dollars a year. The high incidence and increasing cost of
CVI care has renewed interest in this disease process and
much has been learned in the past decade.
Primary valvular incompetence with or without obstruc-
tion causes ambulatory venous hypertension in the lower
extremity. Increased pressure is transmitted to the dermal
microcirculation resulting in extravasation or red blood cells
(RBCs) and macromolecules. RBCs and macromolecules
cause an injury to the dermal architecture resulting in micro-
circulatory activation of adhesion molecules and leukocyte
recruitment. Activated leukocytes in conjunction with in-
creased extra-cellular matrix tension may be the underlying
cause of venous ulcer formation.Recently publisheddata from
our laboratory indicates that CVI disease progression is asso-
ciated with increased fibroblast mediated contractile proper-
ties and a potential ability to accelerate venous ulcer healing. A
consequence of this adaptive wound healing response is in-
creased stored kinetic energy and tension in dermis of patients
with CVI. In our experiments, we observed gel contraction in
unstipulated gels indicating that fibroblasts surrounded by an
extracellular matrix, exert a baseline degree of tension on their
surrounding environment. This tension is increased when
stimulated with transforming growth factor-1 and/or extra-
cellular signal-regulated kinase inhibition. We believe that an
injury to the CVI dermal architecture releases stored kinetic
energy in the dermis and clinically manifests itself initially as
wound separation. This clinical situation is analogous to a
stretched rubber band. When external forces are used to
stretch a rubber band, tension is exerted on the elastic fibers
within the band.When the rubber band is released, the stored
kinetic energy within the elastic fibers is released and the band
contracts. It is clear that increased fibroblast contractility is
beneficial in healing wounds. However, in patients with der-
mal fibrosis and increasedmatrix tension, an injury that causes
architectural damage may be the underlying stimulus that
releases kinetic energy and causes initial wound separation.
If the above hypothesis is true, then it is logical to
assume that medical or surgical correction of venous hyper-
tension should prevent RBC and macromolecule extrava-
sation and stops the underlying inflammatory injury event.Given the fact that compression therapy is the mainstay of
venous ulcer healing, there seems to be credence to this
hypothesis. Therefore, one must assume that venous re-
ulceration is partially if not completely related to the per-
sistence of venous hypertension in primary CVI. In patients
with PTS, the effectiveness of clot resolution and anticoag-
ulation is another related factor.
PTS is the development of CVI after an episode of deep
venous thrombosis. Patients with PTS can manifest any of
the signs of the CVI from pain and edema to severe
lipodermatosclerosis and venous ulceration. Every clinical
venous study performed has indicated that PTS patients
have worse symptoms and higher venous ulcer recurrence
rates. Why the outcomes are poorer is currently unknown.
In a recent review by Prandoni in the British Journal of
Hematology a proximal venous thrombosis, previous ipsilat-
eral DVT, insufficient oral anticoagulation, and poor vein
recanalization after 6 months of anticoagulation were all
strong predictors for the development of PTS. Based upon
these facts, what are the current road blocks to preventing
re-ulceration in patients with PTS?
1. Pathophysiology of venous ulcer formation. Although
great progress has been made over the past 2 decades, the
pathophysiology of ulcer formation is still poorly under-
stood. Effective medical and surgical therapies cannot be
developed without a better understanding of how end
organ damage is caused by venous hypertension.
2. Ineffective anticoagulation andpoor venous recanalization
strongly suggest that lytic therapy may play a significant
role in decreasing the incidence of PTS. Presumably this
effect is secondary to valve function preservation and/or
the prevention of venous outflow obstruction. Random-
ized trials are currently being conducted to evaluate the
role of venous lysis in the prevention of PTS.
3. Wehave noobjectivemethodor good imaging techniques
for determining venous obstruction. Current data on sur-
gical valve repairs or valve transplants have all depended
heavily on the subjective assessment of vein patency based
on venography. Examination of excised, recanalized veins
have documented high-grade stenoses in damaged veins
despite their patent appearance on venography. To over-
come this road block, I suggest the following:
(a) Re-assess valve repair in conjunction with stenting
and/or endophlebectomy.
(b) Consider re-evaluating angioscopy as a method to
assess venous obstruction. Perhaps the angioscope
can be modified with a side port that can cut
endovenous scar tissue and widen lumen patency.
(c) Consider a natural history study using an intravas-
cular ultrasound scan to assess venous anatomy in
patients with PTS.
4. Compression therapy is currently the gold standard for
ulcer healing and recurrence. Despite this fact, ulcer
recurrence is still seen in compression patients for rea-
sons that are currently unknown. I propose the follow-
ing to overcome this roadblock:
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developing smart stockings that can provide clini-
cians with clinically relevant data. For example, can
stocking fibers that change color when the degree
of compression decreases be developed? Can we
develop remote pressure sensors or holter type
pressure sensors that can be interrogated to deter-
mine the effectiveness of compression much like
holter monitors collect heart rhythm data over a
1-week to 2-week period.(b) Can we develop a technology that measures skin
tension? The greater the dermal fibrosis and scar-
ring the higher the skin tension and, therefore,
the greater the likelihood of a venous ulcer
recurrence.
5. We need an objective way to assess end organ dam-
age. Imaging that identifies high-risk dermal architec-
ture may help clinicians determine which patients are
at risk for developing ulcer recurrences and who are
not.
